Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
BioPharma Dive3d
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin
The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...
The Motley Fool3d
Why Eli Lilly Stock Flopped Today
That morning, Wegovy maker Novo Nordisk announced the latest clinical trial results for an advanced ... fellow obesity drug developers like Eli Lilly in a sympathy sell-off. I don't think ...